Shubao Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Shubao Wang has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Caigang Liu
Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China
2 shared publications - Ping Lu
Department of Surgery Oncology, General Surgery, First Hospital of China Medical University, Shenyang, China
2 shared publications - Di Wu
Department of Cardiology, First Hospital of China Medical University, Shenyang, China
1 shared publication - Hao Zhang
Department of Breast Surgery, Second Hospital of Dalian Medical University, Dalian, China
1 shared publication - Huimian Xu
Department of Oncology, First Affiliated Hospital of China Medial University, Shenyang, China
1 shared publication Junqing Chen
Department of Oncology, First Affiliated Hospital of China Medial University, Shenyang, China
1 shared publication
Latest Publications
- Open Access
- 20 June 2010
- Published by Springer Nature in BMC Cancer
- Vol. 10 (1) , 308
Does D3 surgery offer a better survival outcome compared to D1 surgery for gastric cancer? A result based on a hospital population of two decades as taking D2 surgery for reference
Background: We conducted a retrospective study in our hospital in which we compared D1 with D3 through D2 lymphadenectomy for gastric cancer in terms of morbidity, postoperative mortality, long-term survival after surgery. Methods: 567 patients who were performed curative intent between 1980 and 2003 were enrolled. 187 in the D1 group, 189 in the D2 group and 191 in the D3 group. Every procedure was verified by pathological analyses. The primary endpoints were 5-year overall survival. Results: Median follow-up periods were 36 months and 60 months for D1 group and D3 group. Overall 5-year survival rate was significantly higher in patients underwent D3 surgery than in those performed D1 surgery (37.4% vs 48.7%; log-rank, p = 0.027). For the cases followed up to 120 months, the 10-year overall survival rate was 29% (95% CI, 22.1% to 35.9%) for the D1 group and 33.7% (95% CI, 26.6% to 40.8%) for the D3 group (log-rank, p = 0.005). Conclusions: D1 surgery should be operated only for patients with Borrmann I disease. As D3 gastrectomy is associated with low mortality and adequate survival times when performed in selected institutions that have had sufficient experience with the operation and with postoperative management, we recommend D3 lymphadenectomy for patients with curable gastric cancer.
- 20 June 2010
- Published by Springer Nature in BMC Cancer
- Vol. 10 (1) , 308
Open AccessDoes D3 surgery offer a better survival outcome compared to D1 surgery for gastric cancer? A result based on a hospital population of two decades as taking D2 surgery for reference
Background: We conducted a retrospective study in our hospital in which we compared D1 with D3 through D2 lymphadenectomy for gastric cancer in terms of morbidity, postoperative mortality, long-term survival after surgery. Methods: 567 patients who were performed curative intent between 1980 and 2003 were enrolled. 187 in the D1 group, 189 in the D2 group and 191 in the D3 group. Every procedure was verified by pathological analyses. The primary endpoints were 5-year overall survival. Results: Median follow-up periods were 36 months and 60 months for D1 group and D3 group. Overall 5-year survival rate was significantly higher in patients underwent D3 surgery than in those performed D1 surgery (37.4% vs 48.7%; log-rank, p = 0.027). For the cases followed up to 120 months, the 10-year overall survival rate was 29% (95% CI, 22.1% to 35.9%) for the D1 group and 33.7% (95% CI, 26.6% to 40.8%) for the D3 group (log-rank, p = 0.005). Conclusions: D1 surgery should be operated only for patients with Borrmann I disease. As D3 gastrectomy is associated with low mortality and adequate survival times when performed in selected institutions that have had sufficient experience with the operation and with postoperative management, we recommend D3 lymphadenectomy for patients with curable gastric cancer.
- Open Access
- 24 October 2007
- Published by Springer Nature in BMC Cancer
- Vol. 7 (1) , 200
Clinical implications of metastatic lymph node ratio in gastric cancer
The 5-year survival rate in patients with gastric cancer is still poor, and lymph node metastasis is considered one of the most important prognostic factors. However, there are controversies in the classification of lymph node metastasis in gastric cancer. This study was carried out to investigate whether the metastatic lymph node ratio is a reliable classification of lymph node metastasis in gastric cancer in Chinese.
- 24 October 2007
- Published by Springer Nature in BMC Cancer
- Vol. 7 (1) , 200
Open AccessClinical implications of metastatic lymph node ratio in gastric cancer
The 5-year survival rate in patients with gastric cancer is still poor, and lymph node metastasis is considered one of the most important prognostic factors. However, there are controversies in the classification of lymph node metastasis in gastric cancer. This study was carried out to investigate whether the metastatic lymph node ratio is a reliable classification of lymph node metastasis in gastric cancer in Chinese.